Kentucky is one of the poorest states in the U.S. However, the state has been one of the most successful in reducing its uninsured rate, which happened in part through the Affordable Care Act's Medicaid expansion that took effect on Jan. 1, 2014. In the past, Kentucky has reported low rates of colorectal cancer screening and has ranked among the highest states for incidence and mortality for the disease.
A study by Indiana University School of Medicine and the Regenstrief Institute reviewed and analyzed the findings of 31 studies with a total of 120,255 participants. Each individual had a fecal immunochemical test, which identifies hidden blood in stool. FIT results were compared to the finding of a subsequent screening colonoscopy and were found to have high detection rates for colorectal cancer.
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.
A small, retrospective study at Johns Hopkins has found that, in patients with particular pancreatic duct lesions, the presence of an inherited mutation in a pancreatic cancer susceptibility gene may increase the patients' risk of developing pancreatic cancer.
The American Society of Breast Surgeons published new guidelines recommending that all people diagnosed with breast cancer undergo genetic testing with a multi-gene panel.
Merck announced full results from the pivotal phase III KEYNOTE-426 trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma at the 2019 Genitourinary Cancers Symposium (Abstract #543).
Merck announced the pivotal phase III KEYNOTE-240 trial evaluating Keytruda, Merck's anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival compared with placebo plus best supportive care.
Merck announced the presentation of interim data from the phase Ib/II KEYNOTE-365 umbrella trial investigating Keytruda, the company's anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer.
Bristol-Myers Squibb Co. announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer.
Preliminary data from phase II the GALAHAD study showed that approximately 40 percent of patients with DRD in BRCA1/2 receiving treatment with niraparib (300 mg daily) demonstrated an objective response, defined by the Response Evaluation Criteria in Solid Tumors guideline, version 1.1, as a standard measure of tumor response.
